Microbial eczema is a chronic recurrent dermatosis characterized by evolutionary polymorphism of the elements of the rash, sputum, itching, allergic reaction of the sensitized skin to the products of the decay of microorganisms and their toxins, developing against the background of a long-existing pyogenic focus in violation of the most important regulatory systems of the body.Purpose: to study the biocenosis of the skin in patients with microbial eczema and to evaluate the clinical efficacy and safety of the cream “Tetraderm” in such patients.Materials and methods. Patients with microbial eczema were observed, randomly selected into two groups. All patients studied biocenosis of the skin before and after treatment. Patients of the study group received topical therapy with the cream “Tetraderm”. External therapy for patients of the comparison group was carried out with cream of mometasone furoate in combination with erythromycin and clotrimazole ointments. The effectiveness of the therapy was evaluated taking into account the clinical dynamics of the skin process, bacteriological data on the content of pustules and detachable erosion, calculation of the EASI and DIJ indices.Results. A comparative analysis of the biocenosis of microbial eczema foci in patients of both groups at the end of therapy showed a higher severity of disbiotic changes in the comparison group. As a result of our study found that patients who used the cream “Tetraderm”, there was a more rapid regression of dermatosis, almost complete suppression of pathogenic bacterial flora, a significant improvement in the quality of life.Conclusion. The biocenosis of the skin of patients with microbial eczema was characterized by a high degree of contamination of Staphylococcus aureus and Staphylococcus epidermidis, against the background of the average verification of Streptococcus spp., Candida spp. The combination of pronounced anti-inflammatory, antibacterial, antimicotic and regenerating effects of the cream “Tetraderm” causes its high efficiency and prospects of use as a drug of choice of topical monotherapy of microbial eczema.
Goal. To assess the clinical efficacy of a monotherapy with the use of products belonging to the Hyseac line for the treatment of light acne. Materials and methods. The study involved 28 patients with light acne, who were administered products belonging to the Hyseac line as a monotherapy. The dynamics of the skin processes was assessed visually (S. Liden’s acne general severity scale) and with the use of instrumental methods — sebometry (Callegari SOFT 5.5). Results. High efficacy of the administered therapy was registered in 39% of the subjects, substantial improvement was recorded in 53% of the subjects, improvement — in 8% of the subjects while no effect was registered in 0% of the subjects. Conclusion. The drug demonstrated high clinical efficacy, good tolerance and absence of any adverse effects, which makes it possible to recommend products belonging to the Hyseac line as a monotherapy and concomitant treatment of light acne.
In this article, we report two cases of Norwegian scabies in a 12-year-old girl and a 4-year-old boy. Norwegian scabies is an exceedingly rare variant of widespread parasitic dermatosis. In both patients, the diagnosis was challenging for pediatricians, dermatologists, and allergists due to specific disease pattern and clinical manifestations. We demonstrated the difficulties associated with diagnostics, as well as the importance of thorough examination of patients with severe dermatoses that can mask this variant of scabies. Patients with comorbidities, particularly those using topical corticosteroids for a long time, can be considered as a high-risk group for this highly contagious parasitic dermatosis with severe complications (erythroderma, sepsis, etc.). Awareness of dermatologists and other healthcare specialists, compliance with examination algorithms will ensure timely diagnosis of Norwegian scabies, prevent iatrogenic errors, and improve the epidemiological situation. Key words: children, Norwegian scabies, Down syndrome, diagnostic difficulties
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.